Skip to main content

Table 3 Use of antimalarials among individuals with acute fever and treated with antimalarials (proportion estimates & 95% confidence intervals)

From: Treatment of Febrile illness with artemisinin combination therapy: prevalence and predictors in five African household surveys

 

Gambia

Ghana

Kenya

Nigeria

Uganda

Artemisinin-combination theraphy

     

artemether_amiodaquine

-

-

-

0%(0%, 1%)

-

artemether_lumefantrine

-

4%(-1%)

30%(21%,39%)

8%(4%,11%)

36%(26%,46%)

artesunate_amodiaquine

-

32%(21%,42%)

-

0%(0%,1%)

-

artesunate_mefloquine

-

-

0%(0%,1%)

-

-

dihydroartemisinin_piperaquine

-

5%(1%,9%)

0%(0%,1%)

-

1%(0%,2%)

Other Antimalarials

     

SP

64%(54%,74%)

4%(0%,7%)

13%(6%,20%)

9%(3%,15%)

9%(6%,13%)

chloroquine

97%(95%,100%)

8%(1%,16%)

1%(0%,2%)

39%(29%,48%)

18%(12%,24%)

amodiaquine

-

21%(13%,29%)

13%(8%,18%)

0%(0%,1%)

4%(1%,7%)

antimalarial, unspecified

-

19%(11%,27%)

33%(25%,42%)

38%(27%,48%)

24%(13%,35%)

quinine

1%(0%,1%)

4%(-1%,8%)

11%(6%,15%)

1%(0%,3%)

21%(17%,25%)

artemether

-

3%(0%,5%)

-

3%(0%,6%)

1%(0%,1%)

artemisinin

-

-

1%(0%,2%)

1%(0%,2%)

-

artesunate

-

9%(4%,14%)

-

5%(2%,8%)

-

chloroquine_SP

1%(0%,2%)

-

-

-

0%(0%,1%)

dihydroartemisinin

-

-

2%(0%,3%)

1%(0%,1%)

-

halofantrine

-

-

-

1%(0%,2%)

-

mefloquine

-

-

-

0%(0%,1%)

-

quinine_SP

-

-

2%(0%,3%)

-

-